MONDAY, March 2, 2026 (HealthDay News) -- For people with chronic migraine (CM), taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with fewer emergency department visits and hospitalizations overall and less need for medications used to stop and prevent migraine attacks, according to a study scheduled for presentation at the annual meeting of the American Academy of Neurology, to be held from April 18 to 22 in Chicago.Vitoria Acar, from the University of Sao Paulo in Brazil, and colleagues compared health care utilization, triptan use, and preventive-treatment escalation following initiation of a GLP-1 RA versus topiramate in adults with CM
Rather than binding to a single metabolic receptor, this research peptide is engineered to interact with three distinct receptor targets involved in glucose and lipid metabolism: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
In this article, well break down what DHT is, why it matters, how DHT blockers function, and when they might be used
In Phase 2 clinical trials, retatrutide demonstrated substantial reductions in body weight
As with any cosmetic treatment, it is important to consult with a qualified healthcare professional before undergoing the procedure.